Infoplaza Group

Infoplaza Group (“Infoplaza”) is a multi-media company with more than 100 experts consisting of media meteorologists, editors, IT and designers who provide Weather and Climate news 24/7. With ‘best in class’ technology, the most beautiful visuals are created to convey the news powerfully and clearly.

With solutions for TV and Radio, Web and App, Newspapers and Narrow Casting, this reduces the entire media mix. Infoplaza is also a partner of various media, including DPG Media, Telegraaf Media Groep and NOS.

Infoplaza is the market leader in the Benelux and has expanded this further in recent years through a buy-and-build strategy. Amongst other things due to the acquisition of Weeronline. With the combined development power and the use of complementary knowledge, Infoplaza will be able to further strengthen its market-leading position in the coming years.

Our news

9 April, 2026

819 Capital Partners invests in Wolk

Deventer, 9 April 2026 - Dutch company Wolk has raised €1.75 million to accelerate the deployment of its smart hip airbag in elderly care. The investment round was led by 819 Capital Partners, through 819 Seed Fund I, and the Innovatiefonds Ouderenzorg of CbusineZ (CZ), with participation from Nivogé, Catalyst Impact Investment Club, and several angel investors. Each year in the Netherlands, approximately 120,000 elderly people end up in the emergency department after a fall....

Continue reading
6 March, 2026

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...

Continue reading